Royal Bank of Canada
FBRX icon

Royal Bank of Canada’s Forte Biosciences FBRX Stock Holding History

Royal Bank of Canada’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$346K Buy
13,389
+1,403
+12% +$40.4K ﹤0.01% 4381
2025
Q4 		$327K Buy
11,986
+733
+7% +$12.9K ﹤0.01% 4473
2025
Q3 		$169K Buy
11,253
+2,019
+22% +$23.3K ﹤0.01% 5191
2025
Q2 		$119K Buy
9,234
+5,892
+176% +$50.7K ﹤0.01% 5526
2025
Q1 		$26K Sell
3,342
-442
-12% -$5.22K ﹤0.01% 5823
2024
Q4 		$86K Buy
+3,784
New +$45K ﹤0.01% 5419
2024
Q3 		– Sell
-5
Closed – – 7014
2024
Q2 		$0 Hold
5
– – ﹤0.01% 7194
2024
Q1 		$0 Buy
+5
New +$87 ﹤0.01% 7170
2023
Q3 		– Sell
-6
Closed – – 7217
2023
Q2 		$0 Sell
6
-1
-14% -$26 ﹤0.01% 7369
2023
Q1 		$0 Hold
7
– – ﹤0.01% 7176
2022
Q4 		$0 Sell
7
-2
-22% -$51 ﹤0.01% 7367
2022
Q3 		$0 Buy
9
+2
+29% +$64 ﹤0.01% 7561
2022
Q2 		$0 Sell
7
-46
-87% -$1.46K ﹤0.01% 7466
2022
Q1 		$2K Sell
53
-69
-57% -$2.61K ﹤0.01% 7475
2021
Q4 		$7K Buy
122
+76
+165% +$5.11K ﹤0.01% 7143
2021
Q3 		$4K Buy
46
+15
+48% +$8.31K ﹤0.01% 7192
2021
Q2 		$26K Buy
+31
New +$27.9K ﹤0.01% 6420
2020
Q4 		– Sell
-1
Closed -$1K – 7125
2020
Q3 		$1K Sell
1
-2
-67% -$1.33K ﹤0.01% 6419
2020
Q2 		$1K Sell
3
-15
-83% -$6.7K ﹤0.01% 6415
2020
Q1 		$8K Buy
+18
New +$7.03K ﹤0.01% 5896
2018
Q4 		– Sell
-1
Closed -$5K – 6858
2018
Q3 		$5K Buy
+1
New +$3.81K ﹤0.01% 6253
2018
Q2 		– Hold
0
– – – 6348
2018
Q1 		– Sell
-83
Closed -$384K – 6466
2017
Q4 		$320K Buy
83
+81
+4,050% +$323K ﹤0.01% 4130
2017
Q3 		$7K Buy
+2
New +$8.91K ﹤0.01% 6353
2017
Q2 		– Hold
0
– – – 6616

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Royal Bank of Canada's FBRX Position: Q1 2026 in Review

Royal Bank of Canada increased its Forte Biosciences (FBRX) stake by 12% in Q1 2026, buying an estimated $40.4K and bringing the position to 13,389 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #4381.

Royal Bank of Canada first reported a position in FBRX in Q3 2017 and has held it in 23 quarters since. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Royal Bank of Canada held 13,389 shares of Forte Biosciences worth $346K as of Q1 2026.
  • Royal Bank of Canada bought 1,403 Forte Biosciences shares in Q1 2026, an estimated $40.4K.
  • Forte Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4381 holding.
  • Royal Bank of Canada first reported a position in Forte Biosciences in Q3 2017 and has held it in 23 quarters since.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.